Summary basis of decision (SBD) for Halaven

Health Canada has issued a Notice of Compliance for the drug product, Halaven. Halaven, an antineoplastic agent, is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Read the full document here.